Viridian Therapeutics, Inc.
Clinical trials sponsored by Viridian Therapeutics, Inc., explained in plain language.
A biopharmaceutical company developing antibody therapies for autoimmune and rare diseases.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New shot could tame thyroid eye disease
Disease control OngoingThis phase 3 trial tests an investigational drug called VRDN-003, given as an injection under the skin, for people with thyroid eye disease. The study involves 320 participants and aims to check the drug's safety and tolerability. Researchers will also measure if it reduces eye b…
Phase: PHASE3 • Sponsor: Viridian Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug could ease bulging eyes in thyroid disease
Disease control OngoingThis phase 3 trial tests an investigational drug called VRDN-003 in 204 people with chronic thyroid eye disease (TED). The drug is given as a shot under the skin and aims to reduce eye bulging and other symptoms. Participants are randomly assigned to receive either VRDN-003 or a …
Phase: PHASE3 • Sponsor: Viridian Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New shot could ease bulging eyes in thyroid disease
Disease control OngoingThis Phase 3 trial tests an investigational drug called VRDN-003 for active thyroid eye disease, a condition that causes eye bulging, redness, and discomfort. The study involves 132 adults with moderate to severe symptoms. Participants receive either VRDN-003 or a placebo as a sh…
Phase: PHASE3 • Sponsor: Viridian Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC